Yard signs in Florida depicting the candidates for the 2024 US presidential election (Robert Bell/INSTARimages/Cover Images via AP Images)
November 4, 2024 04:07 PM EST
Pharma
FDA+

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

Nicole DeFeudis

Editor

The bio­phar­ma in­dus­try has been a bi­par­ti­san po­lit­i­cal tar­get in re­cent years. But in the 2024 pres­i­den­tial elec­tion, de­tails are scarce around key is­sues that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times